According to the current state of studies, it seems that glutathione (GSH) is unlikely to be able to cross the blood-brain barrier intact, but that amino acids reach the brain cells.
Tirzepatide for Type 2 Diabetes (Mounjaro) Initiated at 2.5 mg weekly (to build tolerance) Bumped to 5 mg after 4 weeks, then titrated by 2.5 mg every 4 weeks as needed Dose adjustment guided by glycemic control (HbA1c targets) and side effect tolerability Typically used alongside diet and exercise and can be combined with other diabetes medications excluding type 1 diabetes Tirzepatide for Obesity (Zepbound) Initiated similarly at 2.5 mg weekly Increased to 5 mg after 4 weeks, with potential further titrations every 4 weeks in 2.5 mg steps Recommended maintenance doses for weight loss are 5 mg, 10 mg, or 15 mg weekly Also indicated for moderate to severe obstructive sleep apnea (OSA) related to obesity, often with doses of 10 mg or 15 mg Prescribed alongside a reduced-calorie diet and increased physical activity Why Gradual Dose Increases Matter Gastrointestinal side effects (nausea, diarrhea, vomiting) are common during initiation and can be dose-limiting Slow titration allows for better medication tolerance and improved adherence Adjustments are based on individual response and tolerance, highlighting the importance of medically supervised care Special Considerations: Who Needs Careful Monitoring
GLP1 injections are given subcutaneously (under the skin) in one of three areas: the abdomen (at least 5cm from the belly button), the front of the thigh (upper leg), or the back of the upper arm (if administered by another person)
We'll share more about what's ahead on 12/17 at 2:30 eastern / 11:30 pacific: For those who have taken the eligibility survey but not consented yet there are a few spots left
(verified owner) Very happy with this company and product
